Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Male or female ≥ 18 years of age with a diagnosis of B-cell CLL established according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and documented within medical records
CLL that warrants treatment (consistent with accepted IWCLL criteria for initiation of therapy)
Prior treatment for CLL comprising any of the following:
Prior treatment with ≥ 1 regimen containing a therapeutic anti-CD20 antibody or
CLL progression < 24 months since the completion of the last prior therapy for CLL
Appropriate for noncytotoxic-containing therapy based on the presence of any of the following factors:
Grade ≥ 3 neutropenia or thrombocytopenia attributable to cumulative myelotoxicity from prior administration of cytotoxic agents (as documented by bone marrow biopsy obtained since last prior therapy), or
Estimated creatinine clearance < 60 mL/min (as determined by the Cockcroft-Gault method), or
A Cumulative Illness Rating Scale (CIRS) score of > 6
A negative serum pregnancy test for female subjects of childbearing potential
Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Lactating females must agree to discontinue nursing before the study drug is administered.
Evidence of a personally signed informed consent
Known hypersensitivity to the idelalisib, its metabolites, or formulation excipient(s)
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Known myelodysplastic syndrome
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
Ongoing drug-induced pneumonitis
Ongoing inflammatory bowel disease
History of anaphylaxis in association with previous administration of monoclonal antibodies